Results 1 to 10 of about 39,119 (216)

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

New England Journal of Medicine, 2021
BACKGROUND Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. METHODS In an open-label, phase 3, randomized, controlled trial involving persons
Payam Nahid, Patrick P J Phillips, Kelly E Dooley   +2 more
exaly   +2 more sources

The Persister Character of Clinical Isolates of Staphylococcus aureus Contributes to Faster Evolution to Resistance and Higher Survival in THP-1 Monocytes: A Study With Moxifloxacin

Frontiers in Microbiology, 2020
Staphylococcus aureus may cause relapsing infections. We previously showed that S. aureus SH1000 surviving intracellularly to bactericidal antibiotics are persisters.
Tiep K. Nguyen, Tiep K. Nguyen, Frédéric Peyrusson, Magali Dodémont, Nhung H. Pham, Nhung H. Pham, Hoang A. Nguyen, Paul M. Tulkens, Françoise Van Bambeke   +8 more
doaj   +2 more sources

Towards human cardiac new approach methodologies (NAMs) to evaluate the combination of repolarization prolonging and shortening drugs: a pilot study [PDF]

Frontiers in Drug Discovery
Background and PurposeNonclinical human cardiac new approach methodologies (NAMs), including human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with multielectrode array (MEA) represent a highly predictive in vitro model for ...
Robert M. Geiger, Carlos Serna, Bhavya Bhardwaj, Tromondae K. Feaster, Ksenia Blinova   +4 more
doaj   +2 more sources

Synthesis of Bi-Metallic-Sulphides/MOF-5@graphene Oxide Nanocomposites for the Removal of Hazardous Moxifloxacin

Catalysts, 2023
The development of new and advanced materials for various environmental and energy applications is a prerequisite for the future. In this research, the removal of hazardous moxifloxacin (MOX) is accomplished by synthesizing new hybrids of MOF-5 i.e., Ni ...
A. Anum, M. Nazir, Sobhy M. Ibrahim, S. Shah, A. Tahir, Misbah Malik, Muhammad Ahmad Wattoo, Aziz Ur Rehman   +7 more
semanticscholar   +1 more source

Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.

MMWR. Morbidity and mortality weekly report, 2022
On May 5, 2021, CDC's Tuberculosis Trials Consortium and the National Institutes of Health (NIH)-sponsored AIDS Clinical Trials Group (ACTG) published results from a randomized controlled trial indicating that a 4-month regimen containing rifapentine ...
Wendy Carr, E. Kurbatova, Angela M. Starks, N. Goswami, Leeanna Allen, C. Winston   +5 more
semanticscholar   +1 more source

Formulation and Evaluation of Moxifloxacin Loaded Bilosomes In-Situ Gel: Optimization to Antibacterial Evaluation

Gels, 2022
In this study, moxifloxacin (MX)-loaded bilosome (BS) in situ gel was prepared to improve ocular residence time. MX-BSs were prepared using the thin-film hydration method.
A. Zafar, O. Alsaidan, S. Imam, Mohd. Yasir, K. S. Alharbi, M. Khalid   +5 more
semanticscholar   +1 more source

Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species

Antimicrobial Agents and Chemotherapy, 2022
Moxifloxacin is central to treatment of multidrug-resistant tuberculosis. Effects of moxifloxacin on the Mycobacterium tuberculosis redox state were explored to identify strategies for increasing lethality and reducing the prevalence of extensively ...
Somnath Shee, Samsher Singh, A. Tripathi, Chandrani Thakur, Anand Kumar T, Mayashree Das, Vikas Yadav, S. Kohli, R. S. Rajmani, N. Chandra, Harinath Chakrapani, K. Drlica, Amit Singh   +12 more
semanticscholar   +1 more source

Oral absorption and drug interaction kinetics of moxifloxacin in an animal model of weightlessness

Scientific Reports, 2021
To investigate the effect of simulated weightlessness on the pharmacokinetics of orally administered moxifloxacin and the antacid Maalox or the antidiarrheal Pepto-Bismol using a tail-suspended (TS) rat model of microgravity.
Dong Liang, Jing Ma, Bo Wei
doaj   +1 more source

Activity of Moxifloxacin Against Biofilms Formed by Clinical Isolates of Staphylococcus aureus Differing by Their Resistant or Persister Character to Fluoroquinolones

Frontiers in Microbiology, 2021
Staphylococcus aureus biofilms are poorly responsive to antibiotics. Underlying reasons include a matrix effect preventing drug access to embedded bacteria, or the presence of dormant bacteria with reduced growth rate.
Tiep K. Nguyen, Tiep K. Nguyen, Frédéric Peyrusson, Wafi Siala, Nhung H. Pham, Hoang A. Nguyen, Paul M. Tulkens, Françoise Van Bambeke   +7 more
doaj   +1 more source

Dose- and time-dependent manners of moxifloxacin induced liver injury by targeted metabolomics study

Frontiers in Pharmacology, 2022
Moxifloxacin is the most widely prescribed antibiotics due to its excellent oral bioavailability and broad-spectrum antibacterial effect. Despite of its popularity, the rare and severe liver injury induced by moxifloxacin is a big concern that cannot be ...
Ting Hu, Yuan Sun, Zhuoling An
doaj   +1 more source